T cell proliferation induced by anti-cd3 antibodies: requirement for a t-t cell interaction
β Scribed by Jacques Bentin; John H. Vaughan; Constantine D. Tsoukas
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 690 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
β¦ Synopsis
In the presence of interleukin 2 (IL2), soluble anti-CD3 monoclonal antibodies can stimulate highly purified normal T lymphocytes to proliferate. In these experiments HLADR' T cells constituted 13 to 20% of the total cell population, and other HLADR' cells, such as monocytes and B lymphocytes, constituted less than 1% of the population. When the HLADR' T cells were removed from the total T cell population by cytofluorometric sorting, the residual HLA DR-T cells failed to respond to soluble anti-CD3 plus IL2. When the separated HLADR' T cells were recombined with the HLADR-T cells, a response was again found. This response was dependent on the dose of HLADR' T cells added in the mixture. Irradiation individually of the HLA DR' and DR-T cells revealed that the proliferation in the cell mixture was predominantly, if not exclusively, by the HLADR-T cells. The ability of the HLADR' T cells to provide a signal necessary to this proliferation was radioresistant. These data indicate that under the conditions of these experiments HLA DR' ("activated") T cells provide a signal necessary to the responsiveness of previously resting T cells.
π SIMILAR VOLUMES
Monoclonal antibodies (mAb) directed against the T cell differentiation antigen CD28 (Tp44) induce proliferation of resting T lymphocytes in the presence of phorbol esters. Moreover, it has been reported that such antibodies augment and sustain T cell proliferation induced by soluble antigens, phyto
In the perspective of therapeutic in vivo targeting for T-cell attack, the monoclonal antibody (MAb) MOvI8, selected for i t s restricted reactivity with human ovarian carcinoma, and an anti-T3 MAb were used t o produce heteroconjugate or hybrid antibodies derived by fusion of relevant hybridomas. S
CD28 and CTLA-4 are opposing regulators of T cell activation, triggered by the two ligands CD80 and CD86. How these ligands promote either T cell activation via CD28 or inhibition via CTLA-4 is not understood. Using CD80 and CD86 molecules expressed on transfected cells, we have identified a major d